Skip to main content
. Author manuscript; available in PMC: 2009 Mar 1.
Published in final edited form as: Horm Behav. 2007 Dec 14;53(3):481–488. doi: 10.1016/j.yhbeh.2007.12.001

Fig. 2.

Fig. 2

EOD waveform responses to intramuscular injections of 5-HT receptor agonists and antagonists vary depending on which receptor is targeted. Data are shown as mean ± 95% confidence intervals of combined data measured as responses to pharmacological challenge relative to individual baseline [(peak − baseline)/baseline]. Responses presented as thick black lines and solid black circles represent challenge responses that were significantly different (p<0.05) than responses to saline control determined by Dunnett’s t-test. Injections of 5HT2 receptor-specific agents differentially modulate the EOD waveform. Injections of MK212 or DOI had no effect on either amplitude or τP2, while injections of α-Me-5-HT enhanced EOD amplitude, but not τP2. 5HT1A receptor-specific agents modulated EOD waveform in opposite directions. The low and high dose of the 5HT1A agonist 8-OH-DPAT inhibited amplitude, while all three doses inhibited τP2 response to challenge. Conversely, the highest dose of the 5HT1AR antagonist, WAY100635, enhanced both amplitude and τP2.